All conditions

Haemophilia

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

870
Trials on record
91
Recruiting now
5
Australian sites
20
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Haemophilia →

Get alerts when Haemophilia trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Haemophilia

Haemophilia is a rare inherited condition where the blood does not clot properly. Most people's blood contains proteins called clotting factors that help stop bleeding when they are injured. People with haemophilia have low levels of one of these proteins, which means bleeding can last longer than usual after an injury or surgery. In some cases, bleeding can also happen inside the body, particularly in joints and muscles, even without an obvious cause. There are two main types — Haemophilia A and Haemophilia B — depending on which clotting factor is affected.

In Australia, haemophilia is relatively uncommon, affecting around 3,000 to 4,000 people. It is most often diagnosed in males, as it is usually passed down through families via the X chromosome, though females can also be affected or can carry the gene and pass it on to their children. Haemophilia can range from mild to severe, and the symptoms a person experiences will often depend on how much clotting factor their body produces.

Treatment in Australia is generally managed through specialised haemophilia treatment centres, which bring together doctors, nurses, and other health professionals with expertise in the condition. The most common approach to treatment involves replacing or boosting the missing clotting factor, either to treat bleeding when it occurs or to help prevent it happening in the first place. Newer types of medications have also become available in recent years that work in different ways to help manage bleeding. Your medical team will work with you to find the approach that best suits your individual circumstances.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Haemophilia in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Haemophilia currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Haemophilia.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Haemophilia by country. Australia is highlighted.

Showing the top 10 of 62 countries with trial sites.

Clinical trials for Haemophilia

Showing 118 of 118 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT04083781 · Novo Nordisk A/S Phase 3 · 29 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 27 December 2021
Algeria🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇦 CA🇭🇷 HR🇨🇿 CZ🇩🇰 DK +21 more

**Who might be able to join this trial:** - You must agree to participate and sign a consent form before any trial activities begin (a parent or guardian may sign for younger participants). - You must be male and aged 12 years or older at the time of signing the consent form. - You must have been born with Haemophilia...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01027364 · Bioverativ Therapeutics Inc. Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 1 July 2012
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE Hong Kong +9 more

**Who might be able to join this trial:** - You are male and at least 12 years old, and you weigh at least 40 kg (about 88 lbs) - You have been diagnosed with hemophilia B, with a very low level of Factor IX in your blood (2% or less) - You have previously been treated with a Factor IX product on at least 100 separate...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01181128 · Bioverativ Therapeutics Inc. Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 1 August 2012
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇫🇷 FR🇩🇪 DE Hong Kong +11 more

Who might be able to join this trial: - You are male and at least 12 years old, and weigh at least 40 kg (about 88 lbs) - You have been diagnosed with severe hemophilia A, meaning your body produces very little or no Factor VIII (the clotting protein) - You have previously been treated with a Factor VIII product on at...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01425723 · Bioverativ Therapeutics Inc. Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 1 October 2017
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE Hong Kong +10 more

Who might be able to join this trial: - You must have already completed one of the following specific clinical trials: study 998HB102, study 9HB02PED, or another study involving the treatment called rFIXFc - You must be able to understand what the study involves and its risks, and be willing to sign and date a consent...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01440946 · Bioverativ Therapeutics Inc. Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 1 November 2014
🇦🇺 AU🇮🇪 IE🇳🇱 NL🇿🇦 ZA🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - The patient must have severe Hemophilia B, meaning their body produces very little or none of the blood-clotting protein called Factor IX (2% or less of the normal amount) - The patient must be male and younger than 12 years old, and weigh at least 13 kilograms (about 28.6 pounds...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01454739 · Bioverativ Therapeutics Inc. Phase 3 · 22 countries Completed
Completed Phase 3 Est. completion 1 October 2017
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇫🇷 FR🇩🇪 DE Hong Kong +14 more

Who might be able to join this trial: - You must have already taken part in and completed one of four specific previous studies related to rFVIIIFc (trial numbers NCT01181128, NCT02083965, NCT01458106, or NCT02502149) - You must be able to understand the purpose and risks of the study and be willing to sign a consent f...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01486927 · CSL Behring Phase 3 · 20 countries Completed
Completed Phase 3 Est. completion 1 December 2014
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇨🇿 CZ🇩🇪 DE🇭🇺 HU🇮🇹 IT🇯🇵 JP +12 more

**Who might be able to join this trial:** - You have been diagnosed with severe hemophilia A, meaning your Factor VIII activity level is less than 1% (as shown in your medical records). - You are male and between 18 and 65 years old (for Parts 1 and 2 of the trial). - You are male and between 12 and 65 years old (for P...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01489111 · Novo Nordisk A/S Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 10 December 2018
🇦🇺 AU🇧🇷 BR🇧🇬 BG🇭🇷 HR🇩🇰 DK🇫🇷 FR🇩🇪 DE🇭🇺 HU +13 more

**Who might be able to join this trial:** - You have agreed to take part and given your consent before any trial-related activities begin - You are currently taking part in the pathfinder™2 or pathfinder™4 trial and have already received at least 5 doses of the study drug called N8-GP - You are scheduled for a major su...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01662531 · CSL Behring Phase 3 · 10 countries Completed
Completed Phase 3 Est. completion 1 October 2014
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT +2 more

**Who might be able to join this trial:** - The participant must be male and younger than 12 years old. - They must have severe Hemophilia B, meaning their Factor IX (a blood clotting protein) works at 2% or less of normal levels. - They must weigh at least 10 kilograms (about 22 pounds). - They must have already been...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01741545 · Bristol-Myers Squibb Phase 3 · 8 countries Completed
Completed Phase 3 Est. completion 31 January 2015
🇦🇺 AU🇫🇷 FR🇮🇹 IT🇳🇱 NL🇷🇴 RO🇷🇺 RU🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - You have severe hemophilia, meaning your body produces less than 1% of the normal level of the clotting factor affected. - You have been infected with the hepatitis C virus (HCV) and also have hemophilia. - You are male and 18 years of age or older. - You have never previously be...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02083965 · Bioverativ Therapeutics Inc. Phase 1 · 3 countries Completed
Completed Phase 1 Est. completion 1 October 2014
🇦🇺 AU🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with severe hemophilia A - You have previously been treated with clotting factor products (either made from donated blood or lab-made) on at least 150 separate, documented occasions before the study starts - You have never had a positive test for an "i...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02093897 · CSL Behring Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 1 August 2015
🇦🇺 AU🇦🇹 AT🇫🇷 FR🇬🇪 GE🇩🇪 DE🇮🇹 IT🇱🇧 LB🇲🇾 MY +11 more

**Who might be able to join this trial:** - You have been diagnosed with severe hemophilia A, meaning your Factor VIII levels are less than 1% (confirmed in your medical records) - The patient is a boy under 12 years of age - The patient has already been treated with a Factor VIII product more than 50 times before - Fo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02137850 · Novo Nordisk A/S Phase 3 · 23 countries Completed
Completed Phase 3 Est. completion 7 June 2023
Algeria🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇦 CA🇫🇷 FR🇩🇪 DE +15 more

Who might be able to join this trial: - A parent or guardian must give their consent before any trial-related activities take place - The patient must be a boy under 6 years old at the time consent is signed - The patient must have been diagnosed with severe haemophilia A (meaning their clotting factor VIII level is 1%...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02141074 · Novo Nordisk A/S Phase 3 · 24 countries Completed
Completed Phase 3 Est. completion 27 October 2022
Algeria🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇦 CA🇫🇷 FR🇩🇪 DE +16 more

**Who might be able to join this trial:** - A parent or guardian must agree to participate and sign a consent form before any trial activities begin - The patient must be a boy under 6 years old at the time of signing the consent form - The patient must have been diagnosed with Haemophilia B, with a very low level of c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02172950 · CSL Behring Phase 3 · 25 countries Completed
Completed Phase 3 Est. completion 19 January 2021
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇬🇪 GE🇩🇪 DE🇭🇺 HU +17 more

**Who might be able to join this trial:** - Male patients of any age with severe hemophilia A (meaning their body produces less than 1% of the normal clotting factor) who took part in a previous related clinical study using this same treatment (rVIII-SingleChain). - Male patients aged 0 to under 65 with severe hemophi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02234323 · Bioverativ, a Sanofi company Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 23 September 2019
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇹 IT🇳🇱 NL +6 more

**Who might be able to join this trial:** - A parent or legal guardian must be able to understand the study's purpose and risks, and be willing to sign a consent form allowing the use of their child's health information. - The participant must weigh at least 3.5 kg (about 7.7 lbs) at the time of screening. - The partic...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02343406 · AbbVie Phase 2 · 21 countries Completed
Completed Phase 2 Est. completion 24 June 2019
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇮 FI🇫🇷 FR🇩🇪 DE +13 more

Who might be able to join this trial: **Adults (18 years and older):** - People who have been diagnosed with a type of brain tumour called glioblastoma (confirmed by laboratory testing of tumour tissue), where the tumour has clearly come back or grown again. - People whose tumour came back at least 3 months after fini...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02502149 · Bioverativ Therapeutics Inc. Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 1 April 2017
🇦🇺 AU🇳🇿 NZ🇺🇸 US

Who might be able to join this trial: - You have a severe form of Hemophilia A, confirmed by a blood test at the study clinic showing very low levels of a clotting protein called Factor VIII (less than 1%). - You have previously been treated with Factor VIII products (from any source) on at least 150 separate occasions...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02585960 · Baxalta now part of Shire Phase 3 · 22 countries Completed
Completed Phase 3 Est. completion 5 August 2018
🇦🇺 AU🇦🇹 AT🇧🇬 BG🇫🇷 FR🇩🇪 DE Hong Kong🇭🇺 HU🇮🇱 IL +14 more

**Who might be able to join this trial:** *For people already in a BAX 855 study who are moving into this trial:* - The person has completed their final visit in a previous BAX 855 study, or is currently in the Baxalta Continuation Study 261302. - The person is currently using BAX 855 either to treat bleeds as they ha...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02622321 · Hoffmann-La Roche Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 25 October 2016
🇦🇺 AU Costa Rica🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇳🇿 NZ🇵🇱 PL +6 more

**Who might be able to join this trial:** - You weigh at least 40 kilograms (about 88 pounds) at the time of screening - You have been diagnosed with hemophilia A (present from birth, of any severity) and have a documented history of high-level inhibitors (proteins that block clotting factor treatment), measured at 5...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02847637 · Hoffmann-La Roche Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 15 September 2017
🇦🇺 AU Costa Rica🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇹 IT🇯🇵 JP🇵🇱 PL +6 more

**Who might be able to join this trial:** - You weigh at least 40 kilograms (about 88 pounds) at the time of screening - You have been diagnosed with severe congenital (present from birth) hemophilia A - You have clear records of your hemophilia treatment and bleeding episodes from at least the past 24 weeks - Your bl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03020160 · Hoffmann-La Roche Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 15 December 2017
🇦🇺 AU🇧🇪 BE🇯🇵 JP🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You weigh at least 40 kilograms (about 88 pounds) at the time of your screening appointment - You have been diagnosed with severe hemophilia A from birth, or hemophilia A where your body has developed antibodies (called inhibitors) that block the usual treatment - You are al...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03417245 · Genzyme, a Sanofi Company Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 26 January 2021
🇦🇺 AU🇨🇳 CN🇩🇰 DK🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇳 IN🇮🇱 IL +11 more

**Who might be able to join this trial:** - You are male and at least 12 years old - You have been diagnosed with severe hemophilia A or B, confirmed by a blood test showing very low levels of the relevant clotting factor - You do not have inhibitors (antibodies that block clotting factor treatments), confirmed by a sp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03549871 · Genzyme, a Sanofi Company Phase 3 · 15 countries Completed
Completed Phase 3 Est. completion 20 January 2022
🇦🇺 AU🇨🇳 CN🇩🇰 DK🇫🇷 FR🇮🇪 IE🇮🇱 IL🇮🇹 IT🇯🇵 JP +7 more

**Who might be able to join this trial:** - You are male and aged 12 years or older. - You have been diagnosed with severe hemophilia A or B, confirmed by specific blood test results showing very low levels of the clotting factor (Factor VIII below 1% or Factor IX at or below 2%). - If you have developed antibodies th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04759131 · Bioverativ, a Sanofi company Phase 3 · 15 countries Completed
Completed Phase 3 Est. completion 18 January 2023
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇪 IE🇮🇹 IT🇳🇱 NL +7 more

**Who might be able to join this trial:** - The child must be under 12 years old at the time of signing the consent form. - The child must have severe hemophilia A, confirmed by a blood test showing very low or absent clotting Factor VIII, or by a known genetic result that causes severe hemophilia A. - The child must h...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05768386 · BioMarin Pharmaceutical Not Applicable · 12 countries By Invitation
By Invitation Not Applicable Est. completion 1 January 2040
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇿🇦 ZA +4 more

**Who might be able to join this trial:** - You must have either already finished a related main treatment study, or be currently enrolled in that main study when it closes — and you can still join even if you have gone back to using regular hemophilia A treatments. - You must be able to understand and agree to the stu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05145127 · Pfizer Phase 3 · 24 countries Recruiting
Recruiting Phase 3 Est. completion 31 July 2030
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇭🇷 HR🇩🇰 DK🇫🇷 FR +16 more

**Who might be able to join this trial:** - You meet the minimum body weight requirement set by the related ("parent") studies. - You are willing and able to attend all scheduled visits, follow the treatment plan, and complete all required tests and procedures. - You successfully completed a related ("parent") study wi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05568719 · Pfizer Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 25 February 2040
🇦🇺 AU🇨🇦 CA🇰🇷 KR🇸🇪 SE🇹🇼 TW Turkey (Türkiye)🇺🇸 US

Who might be able to join this trial: - You must have previously received the experimental gene therapy treatment (either giroctocogene fitelparvovec or fidanacogene eleparvovec) as part of a specific Pfizer-sponsored clinical study (one of the following studies: C0371002, C0371003, C0371005, C3731001, or C3731003). W...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05611801 · Pfizer Phase 3 · 18 countries Recruiting
Recruiting Phase 3 Est. completion 10 September 2028
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇩🇰 DK🇩🇪 DE +10 more

**Who might be able to join this trial:** - Participants must be male and meet a minimum weight requirement for their age group. - Teenagers aged 12 to 17 must weigh at least 25 kg (about 55 lbs) at the time of signing up. - Children aged 6 to 11 must weigh at least 19 kg (about 42 lbs) at the time of signing up. - Th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06003387 · CSL Behring Phase 3 · 14 countries Recruiting
Recruiting Phase 3 Est. completion 4 October 2028
🇦🇺 AU🇧🇷 BR🇧🇬 BG🇨🇦 CA Hong Kong🇮🇱 IL🇲🇽 MX🇸🇦 SA +6 more

**Who might be able to join this trial:** - You must be considered a legal adult according to the laws of your country. - You must have been born with Hemophilia B and have a severe or moderately severe lack of clotting Factor IX (FIX) — specifically, your FIX levels must be at or below 2% of normal. - You must curren...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06379789 · Regeneron Pharmaceuticals Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 14 August 2034
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with severe or moderately severe hemophilia B, meaning your Factor IX (FIX) activity level is very low (2% or less), or your genetic test confirms you have severe hemophilia B - You are currently taking regular preventive Factor IX treatment (called p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03597022 · Bayer Phase 2 · 11 countries Terminated
Terminated Phase 2 Est. completion 15 October 2019
🇦🇺 AU🇦🇹 AT🇧🇬 BG🇫🇷 FR🇭🇺 HU🇮🇹 IT🇯🇵 JP🇳🇿 NZ +3 more

**Who might be able to join this trial:** - You are a male with severe hemophilia A (with very low Factor VIII activity) or severe hemophilia B (with very low Factor IX activity), with or without inhibitors (antibodies that block clotting factors) - You have had inhibitors in the past (at any level), even if you no lon...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02207894 · Haemophilia Centre Rhine Main Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇪 DE

"Who might be able to join this trial: - You are male, at any age, and have been diagnosed with haemophilia A (a condition where the blood does not clot properly due to low levels of a protein called Factor VIII). - Your haemophilia A is classified as severe, moderate, or mild based on your Factor VIII levels (as measu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02453542 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇸🇪 SE

Who might be able to join this trial: - You (or your guardian) must be willing and able to give informed consent to take part in the study - You must meet the description of the group of people this study is looking for (confirm with trial site) Who may not be able to join: - You are not willing or able to give inform...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02912143 · Goethe University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with hemophilia A or hemophilia B - Your level of clotting factor VIII or factor IX is between less than 1% and 25% of normal - You are willing and able to give your informed consent to take part in the trial Who may not be able to join: - You are not wil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02979119 · PedNet Haemophilia Research Foundation Not Applicable · 19 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2039
🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇮 FI🇫🇷 FR🇩🇪 DE +11 more

Who might be able to join this trial: - People who have been diagnosed with Haemophilia A or B - People whose Factor VIII or Factor IX activity level is between less than 1% and 25% - People who have complete records of their factor treatment history and bleeding episodes - People who are currently being treated at one...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03217032 · Shenzhen Geno-Immune Medical Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are able to give your agreement to take part and are willing to follow the study's requirements - You are male, aged 2 years or older, and have been confirmed to have hemophilia A with very low levels of factor VIII (2% or less of the normal amount) - You have had an aver...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03327779 · World Federation of Hemophilia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇨🇦 CA

Who might be able to join this trial: - You are a patient at one of the Hemophilia Treatment Centres that is taking part in this trial, and you have been diagnosed with Hemophilia A, Hemophilia B, or von Willebrand Disease. Who may not be able to join: - There are no specific exclusion criteria listed for this trial....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03549858 · McMaster University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇦 CA

Who might be able to join this trial: - People with hemophilia (referred to as PWH) who are reachable through national hemophilia patient organizations, their membership lists, social media, or events and meetings. Who may not be able to join: - People outside certain age ranges — for example, those under 18 years of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03695978 · Octapharma Not Applicable · 18 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇦🇷 AR Azerbaijan Belarus🇧🇪 BE🇨🇦 CA🇭🇷 HR🇪🇪 EE🇫🇷 FR +10 more

**Who might be able to join this trial:** - Men, women, and children of any age or ethnic background may be eligible - You must have severe haemophilia A, meaning your body produces very little or none of a blood-clotting protein called Factor VIII - Your doctor must have already decided to prescribe an Octapharma Fact...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03961243 · Shenzhen Geno-Immune Medical Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to give informed consent and follow the study requirements - Males aged 2 years or older who have a confirmed diagnosis of hemophilia B, with factor IX levels at or below 2% of normal - People who have had an average of at least 4 bleeding episodes per ye...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04023019 · Emory University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇪 DE🇺🇸 US

**Who might be able to join this trial:** - Male people diagnosed with haemophilia A of any level of severity, who have had a history of inhibitor levels of 0.6 BU/mL or higher — including those whose previous immune tolerance induction (ITI) treatment did not work (confirm with trial site for exact inhibitor measurem...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04131036 · Washington Institute for Coagulation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are male - You have severe hemophilia A, meaning your Factor VIII levels are below 1% - You are 16 years old or older - You are currently taking either Factor VIII or emicizumab as a regular preventive treatment, and you plan to stay on that same treatment for the next 3...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04563520 · Emory University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You have moderately severe Hemophilia A, meaning your body produces very low levels of a clotting protein called Factor VIII - You are 6 years old or older at the time of signing up for the trial - You have been tested on 2 separate occasions and shown to have a high level o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04567511 · Indiana Hemophilia &Thrombosis Center, Inc. Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2025
🇺🇸 US

**Who might be able to join this trial:** - You have signed (or a parent/guardian has signed) a consent form agreeing to take part in the study - You are male - You have been diagnosed with mild congenital hemophilia A, meaning your body produces between 5% and 30% of the normal amount of a clotting protein called Fac...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04645199 · Institute of Hematology & Blood Diseases Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇳 CN

Who might be able to join this trial: - You were diagnosed with one of the following conditions at one of the participating hospitals on or after January 1, 2020: acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, a bleeding disorder, or you received a b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04647227 · American Thrombosis and Hemostasis Network Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with hemophilia A or B with inhibitors - People who are 12 years of age or older - People who are able to understand and follow the study requirements, or who have a parent or legal guardian who is able to do so on their behalf - People who hav...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04676048 · ASC Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2023
🇺🇸 US

**Who might be able to join this trial:** - You are male and at least 18 years old - You have been diagnosed with severe or moderately severe hemophilia A, confirmed by your medical history - You have received treatment (either regular preventive or as-needed) for hemophilia A on at least 150 separate days - If you use...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04728841 · Institute of Hematology & Blood Diseases Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are able to understand what the study involves, including its risks, and are willing to sign a consent form - You are male and at least 18 years old - You have been diagnosed with hemophilia A with very low or absent Factor VIII activity (1% or less), confirmed by a lab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04817462 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇬🇧 GB

**Who might be able to join this trial:** - People who are male and between 18 and 80 years old - People who were previously enrolled and treated in one of three specific gene therapy clinical trials at Royal Free Hospital: the AGT4HB trial (a Factor IX gene therapy trial), the GO-8 trial (a Factor VIII gene therapy tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05022459 · Wayne State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇺🇸 US

Who might be able to join this trial: - You (if aged 18 or older) or your parent/guardian must be willing and able to sign a consent form, and if you are a minor, you should also be willing to give your own agreement to take part where required - You must be male or female, between 6 and 19 years old, and have moderate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05454774 · Institute of Hematology & Blood Diseases Hospital, China Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 15 December 2024
🇨🇳 CN

Who might be able to join this trial: - People who have been fully informed about the trial and have voluntarily signed a consent form agreeing to take part. - Men aged 18 years or older. - People diagnosed with hemophilia A where the body produces very low or no Factor VIII (a clotting protein), at 2% or less of norma...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05500807 · Bleeding and Clotting Disorders Institute Peoria, Illinois Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to sign a consent form agreeing to take part in the study. - You can be any age, including infants, as long as you weigh at least 3 kg (about 6.6 lbs). - In the investigator's opinion, you are able to follow the study's requirements. - You have b...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05621746 · Novo Nordisk A/S Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇦 CA

**Who might be able to join this trial:** - You must be willing to sign a consent form before any study activities take place - You must be male and aged 18 or older at the time of signing the consent form - You must have been diagnosed with severe or moderate congenital haemophilia A (a condition where a clotting prot...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05629130 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇧🇷 BR

Who might be able to join this trial: - People who have an inherited bleeding disorder that has led to joint disease, specifically ongoing joint inflammation caused by repeated bleeding into the joints, with X-ray and MRI results confirming the joint inflammation, and who are being followed up at the Hemophilia Center...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05630651 · Institute of Hematology & Blood Diseases Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are a male between 18 and 65 years old - You have a confirmed diagnosis of Hemophilia B with very low levels of the clotting factor FIX (2% or less) - You have received FIX replacement treatment products on at least 100 separate occasions in the past - In the past year,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05641610 · Institute of Hematology & Blood Diseases Hospital, China Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are male and 18 years of age or older - You have a confirmed diagnosis of hemophilia B with very low levels of the clotting factor FIX (2% or less) - You have been treated with FIX protein products (either lab-made or from plasma) on at least 100 separate occasions in the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05685238 · Novo Nordisk A/S Phase 3 · 32 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇦 CA🇨🇳 CN🇩🇰 DK🇫🇷 FR🇩🇪 DE +24 more

**Who might be able to join this trial:** *For Arms 1 and 2 (existing study participants transferring into this trial):* - People who have given their consent to participate before any study-related activities begin. - People who have been diagnosed with haemophilia A from birth, as confirmed by medical records. - Pe...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05709288 · Institute of Hematology & Blood Diseases Hospital, China Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2035
🇨🇳 CN

**Who might be able to join this trial:** - You (or your guardian) must be able to understand the study's purpose and risks, and sign a consent form - You must be male, between 12 and 17 years old, and weigh at least 50 kg (about 110 lbs) - You must have a confirmed diagnosis of hemophilia B with very low levels of th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05802836 · Christoph Königs Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with severe congenital hemophilia A (a serious inherited bleeding disorder present from birth) - You are currently being treated with a medication called emicizumab (regardless of any other treatments you may be receiving) - You are willing and able to giv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05849740 · Institute of Hematology & Blood Diseases Hospital, China Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with Acquired Hemophilia A (AHA), a condition where the body mistakenly attacks a clotting protein in the blood - Women who have gone through menopause, or women who could become pregnant but are using reliable contraception throughout the trial...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05888870 · Institute of Hematology & Blood Diseases Hospital, China Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with moderate or severe hemophilia A - You are between 14 and 66 years old - You have tested positive for inhibitors (antibodies that block hemophilia treatment) at two separate check-up visits in a row - Your inhibitor level was measured above 10 BU (...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05895032 · East Kent Hospitals University NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇬🇧 GB

Who might be able to join this trial: - Children who are between 6 and 12 years old and have been diagnosed with moderate or severe haemophilia A or B Who may not be able to join: - Children who have a condition called von Willebrand disease - Children who have previously broken a bone or had a serious injury to their...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05935358 · Octapharma Phase 4 · 11 countries Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇭🇷 HR🇫🇮 FI🇫🇷 FR🇩🇪 DE🇮🇳 IN🇮🇹 IT North Macedonia🇷🇸 RS +3 more

**Who might be able to join this trial:** - People who have severe haemophilia A, meaning their Factor VIII (a blood clotting protein) level is less than 1% of normal, based on their medical history - People who are male and at least 12 years old - People who have previously been treated with a Factor VIII product on...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05936580 · Octapharma Phase 4 · 10 countries Recruiting
Recruiting Phase 4 Est. completion 1 February 2027
🇫🇮 FI🇫🇷 FR🇩🇪 DE🇮🇹 IT🇷🇸 RS🇪🇸 ES🇨🇭 CH🇬🇧 GB +2 more

**Who might be able to join this trial:** - You are a woman or girl diagnosed with haemophilia A, with a clotting factor (FVIII) level below 40%, OR between 40–50% if you have a history of significant bleeding problems or have previously needed treatment for haemophilia A - You are at least 12 years old - You are sche...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05981274 · Tri-Service General Hospital (TSGH) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇹🇼 TW

Who might be able to join this trial: - People of any age who have been diagnosed with severe hemophilia A - People who have moderate hemophilia A and have developed joint damage as a result of their condition - People who are currently taking a specific clotting factor treatment called rFVIIIFc on a regular preventati...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05987449 · Hoffmann-La Roche Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 11 December 2033
🇨🇦 CA🇮🇹 IT🇳🇿 NZ🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with severe or moderate congenital hemophilia A (a condition where your blood does not clot properly due to low levels of a protein called Factor VIII). - You may have developed antibodies (called "inhibitors") against Factor VIII treatments, or you m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06008938 · CSL Behring Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2043
🇦🇹 AT🇩🇰 DK🇫🇷 FR🇩🇪 DE🇪🇸 ES🇨🇭 CH🇺🇸 US

**Who might be able to join this trial:** *HEMGENIX Group:* - You have been treated with the commercial (non-trial) version of a medicine called HEMGENIX. - You have signed a consent form either up to 3 months before or within 6 months after receiving HEMGENIX, or within 6 months of the study starting at your location...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06111638 · Shanghai Xinzhi BioMed Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to voluntarily sign a consent form to take part in the study - You are male and aged 18 or older - You have been clinically diagnosed with severe hemophilia A - You have had at least 150 documented treatment sessions using a Factor VIII (clotting factor) produ...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06120582 · Biocad Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
Belarus🇷🇺 RU

**Who might be able to join this trial:** - You are male and have been diagnosed with hemophilia B - You are 18 years of age or older - Your Factor IX (the clotting protein affected in hemophilia B) level is 2% or less, and you do not have inhibitors (antibodies that block the treatment) (confirm with trial site) - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06142552 · Hangzhou Gensciences Biopharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 January 2026
🇨🇳 CN

Who might be able to join this trial: - Men between the ages of 12 and 65 years old - People who have been clinically confirmed to have severe hemophilia A, meaning their Factor VIII activity level is less than 1% (confirmed by lab testing or past medical records) - People who have previously been treated with recombin...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06144125 · Konkuk University Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2026
🇰🇷 KR

Who might be able to join this trial: - People who are scheduled to have heart surgery Who may not be able to join: - People who have thrombocytopenia (a condition where the blood has a lower than normal number of platelets, which help with clotting) - People who are currently taking oral blood-thinning medication (an...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06145373 · Sanofi Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 28 May 2028
🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - You are male and aged 12 years or older at the time of signing the consent form - You have been diagnosed with severe congenital hemophilia A, meaning your body produces less than 1% of the normal level of clotting factor VIII, confirmed by a lab test or medical records - You...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06222697 · Bayer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇰🇷 KR

**Who might be able to join this trial:** - You are 12 years old or older and have hemophilia A - You have previously been treated with Factor VIII (a clotting protein) concentrates, either from plasma or made in a lab - You are already being treated with, or your doctor has decided to start you on, a medicine called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06238908 · Institute of Hematology & Blood Diseases Hospital, China Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form agreeing to take part in the study - You are male and aged 18 or older - You have been diagnosed with severe Hemophilia A, with a clotting factor VIII (FVIII) level below 1% of normal - You have been treated with a FVIII product (either...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06320626 · Kathelijn Fischer Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2026
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with congenital (inherited from birth) haemophilia A, with a very low level of the clotting protein Factor VIII (less than 6 IU/ml) - People who are older than 1 year at the time of joining (children aged 1–16 years may be considered after an interi...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06349473 · Equilibra Bioscience LLC Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 28 September 2026
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** **Part A (healthy volunteers):** - Men between 18 and 55 years old - People with a body weight between 50 kg and 90 kg, and a body mass index (a measure of weight relative to height) between 18 and 30 - People with no significant health problems found during a medical check-up...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06352216 · University Hospital, Bonn Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇩🇪 DE

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with moderate or severe haemophilia A, including if you have developed inhibitors (antibodies that block treatment) or have had a joint replacement - Your medical records fully document how severe your haemophilia is, what tre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06461533 · Takeda Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2029
🇯🇵 JP

Who might be able to join this trial: - People who have been diagnosed with Acquired Haemophilia A and have been treated with a medication called Susoctocog Alfa (also known as Genetical Recombination). Who may not be able to join: - There are no listed exclusion criteria for this trial, meaning no specific groups hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06550882 · Takeda Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with Acquired Hemophilia A (a condition where the body's immune system attacks its own clotting proteins, making it hard to stop bleeding). - People whose doctor has determined they have a medical need to receive the treatment called Obizur. - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06565481 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇭 CH

Who might be able to join this trial: - People who have been diagnosed with Hemophilia Type A or Type B - Adults aged 18 years or older - People who are currently using regular or on-demand treatment to replace clotting factors, or using a non-factor based replacement treatment - People who are able to walk at least 20...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06684314 · Sanofi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 August 2031
🇹🇼 TW

**Who might be able to join this trial:** - You have been diagnosed with moderate or severe hemophilia A, meaning your body makes very little or none of a clotting protein called Factor VIII (5% or less than normal) - You either have never developed inhibitors (antibodies that block treatment) or have not had detectabl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06700096 · Biocad Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 April 2027
🇷🇺 RU🇹🇭 TH

**Who might be able to join this trial:** - You are a man who has been diagnosed with hemophilia B and are 18 years of age or older - Your Factor IX (a clotting protein in the blood) activity level is 2% or lower, meaning your hemophilia is severe - You do not have inhibitors (antibodies that block) Factor IX treatment...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06703606 · Pfizer Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 5 May 2027
🇮🇳 IN Turkey (Türkiye)🇺🇸 US

**Who might be able to join this trial:** - You are male and between 12 and 74 years old, and weigh at least 35 kg (about 77 lbs) at the time of signing the consent form - You have been diagnosed with severe hemophilia A (with very low levels of clotting Factor VIII, below 1%) and do not have inhibitors (antibodies tha...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06706206 · Oxford University Hospitals NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇬🇧 GB

Who might be able to join this trial: - You are willing and able to give your consent to take part in the study. - You are male and aged 45 years or older (there is no maximum age limit). - You have Haemophilia A or B, with a clotting factor level (Factor VIII or IX) below 40%. Who may not be able to join: - You are u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06716814 · Swedish Orphan Biovitrum Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇧🇬 BG🇫🇷 FR🇬🇷 GR🇮🇹 IT🇳🇴 NO🇪🇸 ES🇸🇪 SE

Who might be able to join this trial: - You must be able to give your agreement to take part, or if you are under 18 or unable to give consent yourself, a parent or legal representative must be able to do this on your behalf. - You must have already completed one of four specific previous studies (Sobi.BIVV001-001, Sob...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06727669 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a blood clotting or bleeding disorder (known medically as a thrombosis and hemostasis disease) Who may not be able to join: - People whose long-term follow-up information is not available for any reason, or who have a serious additional illnes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06809972 · Van Creveldkliniek Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇳🇱 NL

**Who might be able to join this trial:** - You are male - You have been diagnosed with severe haemophilia A or B - You are currently taking approved preventive (prophylaxis) medication for haemophilia, such as clotting factor treatments or bypassing agents - You are 12 years old or older - An ultrasound scan done as p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06816056 · Investigación en Hemofilia y Fisioterapia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 July 2025
🇪🇸 ES

Who might be able to join this trial: - You have been diagnosed with haemophilia A or haemophilia B - Your haemophilia is classified as severe, meaning your clotting factor levels are below 1% - You are 18 years of age or older - You have been diagnosed with ankle joint damage related to haemophilia, and your joints ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06833983 · Gritgen Therapeutics Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 November 2026
🇨🇳 CN

Who might be able to join this trial: - People who understand the purpose and risks of the study and have given their formal written consent to participate - People who are male and between 19 and 65 years old at the time of signing the consent form - People who have a confirmed diagnosis of hemophilia A, based on thei...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06864975 · Runhui WU Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2028
🇨🇳 CN

Who might be able to join this trial: - You have a severe form of hemophilia A, meaning your Factor VIII activity level is less than 2% - Your blood has developed inhibitors (antibodies) against Factor VIII treatment - You have not had an allergic reaction to Factor VIII concentrate products in the past Who may not be...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06922045 · Jiangsu BioJeTay Biotechnology Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 12 and 70 years old (inclusive) - You have been diagnosed with Hemophilia A or Hemophilia B - Your inhibitor levels have previously reached 5 BU or higher, and your inhibitor test is positive at the time of enrollment (confirm with trial site) - You are able t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06940830 · Swedish Orphan Biovitrum Phase 4 · 8 countries Recruiting
Recruiting Phase 4 Est. completion 1 December 2028
🇭🇷 HR🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇹 IT🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with haemophilia A. - You are able to read, understand, and sign a consent form agreeing to take part in the study. - You have been prescribed a specific haemophilia medicine called efanesoctocog alfa as a regular preventive treatment, either within th...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06941870 · Sanofi Phase 4 · 4 countries Recruiting
Recruiting Phase 4 Est. completion 25 October 2027
🇨🇦 CA🇯🇵 JP🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with moderate to severe hemophilia A, meaning your body produces 5% or less of the normal level of the clotting protein Factor VIII. - You are 12 years old or older at the time you give your consent to join. - At least one of your joints (such as a kn...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06992076 · Institute of Hematology & Blood Diseases Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with hemophilia A or hemophilia B and whose treating doctor has determined they are suitable to receive preventive treatment (prophylaxis). - People whose treating doctor has prescribed marstacimab for routine preventive treatment, in line with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07032792 · Northwell Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People who are scheduled for planned (non-emergency) heart surgery that does not involve the coronary arteries, where a heart-lung bypass machine will be used - People whose care team has identified excessive bleeding from small blood vessels d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07080905 · CSL Behring Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 24 October 2033
🇦🇹 AT🇧🇪 BE🇮🇱 IL🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** **To enter the first part of the trial (the Lead-in Period):** - People who were assigned male sex at birth - People who are between 11 years and 6 months old, and 17 years and 2 months old, at the time of signing consent - People who were born with hemophilia B and have a sev...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07096349 · Investigación en Hemofilia y Fisioterapia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 October 2025
🇪🇸 ES

Who might be able to join this trial: - Adults aged 18 or older. - People who have been medically diagnosed with severe haemophilia A, meaning their Factor VIII (a blood clotting protein) level is less than 1%. - People who do not currently have inhibitors (substances that block the effects of Factor VIII treatment) at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07099313 · Investigación en Hemofilia y Fisioterapia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 September 2025
🇪🇸 ES

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with hemophilia A or B - You are currently receiving regular (preventive) treatment with clotting factor medicines, whether standard or longer-acting versions, regardless of how mild or severe your hemophilia is - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07101926 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are male - You are at least 18 years old - You have been diagnosed with severe hemophilia A or B (with very low levels of clotting factor VIII or IX in your blood) - You are currently on a regular preventative treatment (prophylaxis) using factor VIII or factor IX concent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07205523 · Yigeng Cao,MD,PhD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2060
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a blood-related disease and were admitted to the HSCT center at Qinghai University Affiliated Hospital on or after September 1, 2023. - You are planning to have, or have already had, a stem cell transplant (a procedure where stem cells are used to rep...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07220564 · Novo Nordisk A/S Phase 1 · 12 countries Recruiting
Recruiting Phase 1 Est. completion 5 February 2027
🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL🇵🇹 PT🇪🇸 ES +4 more

**Who might be able to join this trial:** - People who are male - People who are between 18 and 64 years old (inclusive) at the time of signing the consent form - People who weigh 45 kilograms or more - People who have been diagnosed with congenital haemophilia A (meaning they were born with it) with a factor VIII acti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07226206 · Hoffmann-La Roche Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2031
🇺🇸 US

Who might be able to join this trial: - You must be at least 18 years old at the time of signing the consent form - You must have been assigned male sex at birth - You must have severe or moderately severe hemophilia A, meaning your body produces very little or no Factor VIII (3% or less of normal levels), confirmed by...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07285460 · Sanofi Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 4 August 2029
🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇮🇳 IN🇮🇹 IT🇵🇱 PL🇷🇴 RO +5 more

Who might be able to join this trial: - Children who are at least 1 year old and under 12 years old at the time of joining the study - Children who have been diagnosed with severe hemophilia A or B, confirmed by a blood test or medical records - Children with hemophilia who have developed "inhibitors" (antibodies that...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07314983 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with severe hemophilia A - There is no record in your medical file showing that you have objected to your personal health data being used for scientific research Who may not be able to join: - You have previously stated that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07406139 · Institute of Hematology & Blood Diseases Hospital, China Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 20 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with hemophilia A with inhibitors (where the body's immune system blocks the clotting treatment). People who have previously had high levels of inhibitors must still have a detectable inhibitor level at the time of enrollment (confirm with trial...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07414511 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇺🇸 US

**Who might be able to join this trial:** **Pregnant people (to be enrolled during pregnancy):** - People who are currently pregnant and have not yet reached 37 weeks of pregnancy - People who are known to carry, or may carry, a severe form of the genetic condition hemophilia A - People who are pregnant with at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07416526 · Hoffmann-La Roche Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 23 September 2027
🇯🇵 JP

**Who might be able to join this trial:** - You have been diagnosed with severe or moderate congenital hemophilia A (a hereditary bleeding disorder caused by low levels of a clotting protein called Factor VIII) - You do not currently have "inhibitors" — meaning your body has not developed antibodies that block the clo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07416604 · Hoffmann-La Roche Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 29 February 2028
🇮🇱 IL🇯🇵 JP🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with severe or moderate congenital hemophilia A (a inherited bleeding disorder where the body makes very little or no clotting Factor VIII), with or without antibodies (called inhibitors) that block Factor VIII from working. - You have mild congenital hemo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07437404 · Sinocelltech Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 26 December 2028
🇨🇳 CN

Who might be able to join this trial: - Male patients diagnosed with severe hemophilia A, meaning their Factor VIII levels are less than 1% as confirmed by a central laboratory test - Patients who have never previously been treated with plasma-derived or recombinant Factor VIII products, including a product called SCT8...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07523399 · Yuzuncu Yil University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 April 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with severe hemophilia A - People who are 18 years of age or older - People whose knee or ankle has a joint health score of at least 3 points, as measured by a tool called the Hemophilia Joint Health Score (HJHS) (confirm with trial site) Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07545395 · Suzhou Alphamab Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2027
🇨🇳 CN

Who might be able to join this trial: - You are male, between 12 and 65 years old at the time of signing the consent form, weigh at least 30 kg (about 66 lbs), and have a body mass index (BMI) under 28. - If you have inhibitors (antibodies that block clotting treatments): you have tested positive for high-level or low-...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07579585 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 July 2026
🇵🇰 PK

Who might be able to join this trial: - People who have hemophilia and are experiencing bleeding into the knee joint - Children between the ages of 9 and 14 years old - Both boys and girls are eligible to participate Who may not be able to join: - Children who have open wounds at or near the knee area being treated -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07644832 · Shanghai RAAS Blood Products Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years old at the time of signing the consent form, of any sex - People who have been clinically diagnosed with Hemophilia A or B with very low clotting factor activity levels (FVIII below 1% or FIX at or below 2%), with or without inhibitors — those with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07663903 · Hangzhou Gensciences Biopharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are male and between 12 years old or younger and up to 65 years old - You have been clinically diagnosed with severe hemophilia A, confirmed by a test showing your Factor VIII activity level is less than 1% - You have previously been treated with clotting factor VIII pro...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07682519 · University of Chile Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2027
🇨🇱 CL

Who might be able to join this trial: - Men between the ages of 18 and 60 years old - People who have been diagnosed with hemophilia A or hemophilia B - People who experience ongoing pain that occurs every day, or on at least half of all days, over the past 3 to 6 months - People whose pain involves the elbow, knee, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07684898 · Hangzhou Gensciences Biopharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 9 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - Men between 12 and 65 years of age - People who have been diagnosed with severe hemophilia A, confirmed by blood tests showing clotting factor VIII activity below 1% - People who have previously been treated with clotting factor VIII products (either lab-made or blood-derive...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07723560 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇫🇷 FR

Who might be able to join this trial: - People who have Hemophilia A - People who have had surgery performed using a medicine called Altuvoct® - People who have given their consent to take part after receiving detailed written information about the trial Who may not be able to join: - People who have a blood clotting...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Haemophilia. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Haemophilia Foundation Australia (HFA) is the national body. Separate state and territory foundations also provide local support in NSW, VIC, QLD, WA, SA, TAS, ACT and NT, so it's worth checking which one covers your state.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.